We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+20.07%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$530M
AUM Growth
-$28.3M
Cap. Flow
-$54.8M
Cap. Flow %
-10.35%
Top 10 Hldgs %
67.2%
Holding
99
New
35
Increased
16
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$5.65M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$5.31M
3
VRAY
ViewRay, Inc.
VRAY
+$4.67M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$4.21M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.69M

Top Sells

Rank Stock Value
1
DBVT
DBV Technologies
DBVT
+$8.15M
2
FOLD
Amicus Therapeutics
FOLD
+$3.52M
3
NVTA
Invitae Corporation
NVTA
+$3.37M
4
FBRX icon
Forte Biosciences
FBRX
+$3.13M
5
PDSB icon
PDS Biotechnology
PDSB
+$3.11M

Sector Composition

Rank Sector Weight
1 Healthcare 51.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.83M 0.53%
+155,000
New +$2.4M
ACAD icon
27
Acadia Pharmaceuticals
ACAD
$4.39B
$2.71M 0.51%
90,000
-80,000
-47% -$2.56M
RMTI icon
28
PUT
Rockwell Medical
RMTI
$28.5M
$2.56M 0.48%
4,000
+1,727
+76% +$1.22M
LOXO
29
PUT
DELISTED
Loxo Oncology, Inc
LOXO
$2.52M 0.48%
+30,000
New +$2.5M
FENC icon
30
Fennec Pharmaceuticals
FENC
$333M
$2.5M 0.47%
250,000
– –
ACAD icon
31
CALL
Acadia Pharmaceuticals
ACAD
$4.39B
$2.41M 0.45%
80,000
+10,000
+14% +$320K
AGIO icon
32
PUT
Agios Pharmaceuticals
AGIO
$1.82B
$2.29M 0.43%
+40,000
New +$2.52M
ACRS icon
33
Aclaris Therapeutics
ACRS
$772M
$2.28M 0.43%
+92,500
New +$2.25M
VIVE
34
DELISTED
VIVEVE MED INC
VIVE
$2.15M 0.41%
433
-394
-48% -$2.05M
NKTR icon
35
CALL
Nektar Therapeutics
NKTR
$2.38B
$2.15M 0.41%
+2,400
New +$1.42M
RARE icon
36
CALL
Ultragenyx Pharmaceutical
RARE
$2.46B
$2.13M 0.4%
+46,000
New +$2.26M
BHC icon
37
CALL
Bausch Health
BHC
$2.62B
$2.08M 0.39%
+100,000
New +$1.59M
EDIT icon
38
CALL
Editas Medicine
EDIT
$407M
$1.97M 0.37%
+64,000
New +$1.61M
OSUR icon
39
PUT
OraSure Technologies
OSUR
$286M
$1.89M 0.36%
+100,000
New +$1.81M
CRSP icon
40
CALL
CRISPR Therapeutics
CRSP
$4.88B
$1.88M 0.35%
+80,000
New +$1.52M
NKTR icon
41
PUT
Nektar Therapeutics
NKTR
$2.38B
$1.79M 0.34%
+2,000
New +$1.18M
AMAG
42
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
$1.76M 0.33%
132,500
+82,500
+165% +$1.24M
JUNO
43
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.69M 0.32%
+37,000
New +$1.85M
NTLA icon
44
CALL
Intellia Therapeutics
NTLA
$1.5B
$1.65M 0.31%
+86,000
New +$1.99M
STML
45
CALL
DELISTED
Stemline Therapeutics, Inc.
STML
$1.64M 0.31%
+105,000
New +$1.4M
SGEN
46
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
$1.6M 0.3%
30,000
-40,000
-57% -$2.34M
EXEL icon
47
CALL
Exelixis
EXEL
$13.8B
$1.52M 0.29%
+50,000
New +$1.33M
TDOC icon
48
PUT
Teladoc Health
TDOC
$1.21B
$1.39M 0.26%
40,000
+10,000
+33% +$332K
NVTA
49
DELISTED
Invitae Corporation
NVTA
$1.38M 0.26%
152,300
-375,700
-71% -$3.37M
ALIM
50
DELISTED
Alimera Sciences
ALIM
$1.3M 0.24%
64,955
– –
1
2
3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2017 Portfolio in Review

As of Q4 2017, Acuta Capital Partners held 99 positions worth $530M, down 5.1% from $558M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Acuta Capital Partners withdrew a net $54.8M in Q4 2017, closing 25 positions and reducing 15 holdings. Its most notable exit was DBV Technologies, an estimated $8.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 47% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in AveXis, Inc. Common Stock worth $5.85M.

  • Acuta Capital Partners's largest Q4 2017 buy was AveXis, Inc. Common Stock: 52,900 shares worth $5.85M.
  • Acuta Capital Partners added most to Kadmon Holdings, Inc. in Q4 2017, an estimated $5.65M increase.
  • Acuta Capital Partners's biggest Q4 2017 reduction was Amicus Therapeutics, cutting an estimated $3.52M.
  • Acuta Capital Partners fully exited DBV Technologies in Q4 2017, selling an estimated $8.15M.
  • Acuta Capital Partners's ten largest holdings make up 67% of its $530M portfolio in Q4 2017.
  • Acuta Capital Partners opened 35 new positions and closed 25 in Q4 2017.
  • Acuta Capital Partners's portfolio value fell 5.1% quarter-over-quarter to $530M.

Based on Acuta Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.